IQVIA Reports Growth in Digital Health Solutions
New York, Friday, 20 December 2024.
IQVIA’s 2024 report highlights a surge in digital therapeutics and diagnostics, with over 103 new digital diagnostics available, promising enhanced patient care and disease risk evaluation.
Digital Health Ecosystem Expansion
The digital health landscape has experienced remarkable growth, with IQVIA reporting 337,000 digital health apps available as of December 18, 2024 [1]. A particularly notable development is the emergence of 103 digital diagnostics for disease assessment, leveraging artificial intelligence and machine learning to evaluate health risks and accelerate diagnosis [1]. The market now features 360 software-based digital therapies, with 140 approved for home use and over 220 deployed in clinical settings [1].
Prescription Digital Therapeutics Surge
Since 2021, the industry has witnessed a dramatic five-fold increase in prescription digital therapeutics (PDTs), with 94 new approvals and market access achievements globally [1]. Germany leads this expansion with 51 approvals, though the landscape remains dynamic with some market adjustments [1]. However, the sector faces certain challenges, as evidenced by five products losing temporary reimbursement status in Germany and two others becoming unavailable due to company bankruptcies [1].
Clinical Integration and Market Adaptation
Digital health technologies are increasingly integrated into clinical practice, necessitating robust regulatory frameworks [5]. The market is seeing innovation in patient monitoring tools, with digital solutions now supporting the entire patient journey from diagnosis to disease progression monitoring [1]. New market entrants like Luminopia, Leva Pelvic Health System, and SleepioRx are expanding treatment options for various conditions [1]. IQVIA notes that ‘Approval and reimbursement of digital tools is accelerating as payers recognize clinical utility and cost savings’ [1].
Future Outlook and Global Impact
The digital health sector is poised for further evolution, with significant developments expected in early 2025, including new Health Technology Assessment Regulation implementation [5]. IQVIA, operating with approximately 86,000 employees across more than 100 countries [5], continues to track these developments while emphasizing the importance of evidence-based validation. The company reports that some self-care support apps have already demonstrated positive health impacts through clinical studies [1], suggesting a promising future for digital therapeutics in healthcare delivery.